Other studies showed that a SNP in the IL13 gene (+2044G>A that translates into IL13Q144 protein) of variable frequency in various populations (78) may affect affinity of anti-IL13 monoclonal antibodies (both lebrikizumab and tralokinumab) with IL13 and may therefore affect the efficacy of the antibodies in treating severe asthma (79). This evidence concerns the gene IL13 and asthma.